Wolf Prensky

Over 30 years in basic and applied research, clinical laboratory operations and product development. Dr. Prensky is a highly accomplished scientist having led successful efforts as Director of the HIV Lab at St. Clare’s Hospital in New York City and as a scientific consultant for a number of private investment firms.

Dr. Wolf Prensky plays a key role as KTI advisor, having pioneered the use of I125 for detecting low level RNA-DNA hybrids, applied to gene localization experiments by in situ molecular hybridization, as well as the first fingerprinting mammalian RNAs. He was pivotal in the acquisition by Enzo Biochem of Yale University’s patent for the use of the biotin/avidin system for DNA-RNA labeling. He is also a co-inventor of “DNA dendrimers,” a novel class of reagents capable of high levels of signal amplification in DNA and RNA hybridization experiments (marketed by Genisphere Inc. Hatfield, PA). As a principal of ELONA Pharmaceutical, an investment firm decided to invest in Clofazimine treatment of Clostridium difficile infections and associated disease project to undertake initial studies, help file for provisional patent, is co-inventors on the final patent and is constantly giving guidance on practical aspects of the project.